The Heterogeneity of Diabetes

Unraveling a Dispute: Is Systemic Inflammation Related to Islet Autoimmunity?

  1. Massimo Pietropaolo1,
  2. Emma Barinas-Mitchell2 and
  3. Lewis H. Kuller2
  1. 1Laboratory of Immunogenetics, The Brehm Center for Type 1 Diabetes and Analysis, Division of Metabolism, Endocrinology & Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan
  2. 2Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania
  1. Address correspondence and reprint requests to Massimo Pietropaolo MD, Laboratory of Immunogenetics, The Brehm Center for Type 1 Diabetes and Analysis, 2039 Biomedical Scientific Research Building, 109 Zina Pitcher Place, Ann Arbor, MI 48109. E-mail: maxtp{at}umich.edu

Abstract

Diabetes is an emblematic example of a heterogeneous disease. Systemic inflammation has emerged as a prominent factor in the type 2 diabetes pathoetiology, but it remains ill-defined in type 1 diabetes. There is a wide spectrum of associations between inflammatory responses and diabetic syndromes. At one end of this spectrum, there is type 1 diabetes for which there is convincing evidence that chronic inflammation of pancreatic islets is a central aspect of disease pathogenesis. At the opposite end, is type 2 diabetes that is clearly associated with systemic inflammation, which could be either the cause or simply mark the underlying pathology. Accumulating evidence has substantiated that a subgroup of adult patients clinically diagnosed with type 2 diabetes exhibit autoantibody responses to islet autoantigens. The presence of these immunologic abnormalities is associated with a severe insulin secretory defect and the absence of signs of systemic inflammation as documented by plasma C-reactive protein and fibrinogen levels that are comparable with those of control populations. Islet autoantibody evaluation should be part of the diagnostic assessment for clinically diagnosed type 2 diabetes not only because it might predict the rate of progression to insulin requirement in adult populations but also to identify a pathogenically distinct disease phenotype characterized by the absence of systemic inflammation and its related disorders. A more appropriate characterization of this subgroup of clinically diagnosed type 2 diabetes, diabetes of autoimmune pathogenesis, will promote future research into the etiology, natural history, and treatment.

Footnotes

  • Published ahead of print at http://diabetes.diabetesjournals.org on 23 February 2007. DOI: 10.2337/db06-0880.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted January 26, 2007.
    • Received June 29, 2006.
« Previous | Next Article »Table of Contents